The fact that Neuren are announcing this confirms that they appreciate that the Acadia bad press has hurt perceptions of the Neuren deal.
Great news for Acadia and Neuren. This puts a complete lid on the negative press and provides surety that Nuplazid is here to stay. This secures Acaida as a financially secure partner for Neuren to bring Trofinetide through to market.
Let's see what the market thinks!
Ann: FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID, page-2
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.47 |
Change
0.610(3.07%) |
Mkt cap ! $2.583B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.49 | $19.94 | $2.532M | 125.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 140 | $20.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.48 | 61 | 2 |
View Market Depth
| Last trade - 11.54am 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |